From 2003 to 2016 Dr Moeller also served as Chairman of FIND (Foundation for Innovative New Diagnostics), a PDP with the Bill and Melinda Gates Foundation. In May 2018 Dr Moeller resigned from the Board of Directors of Morphosys AG after 19 years of Service as Chairman. Today he serves on the Board of
4Sigma GmbH,Germany (Chairman); (Healthcare Services)
Ayoxxa AG, Germany (Chairman)
Sphingotec GmbH, Germany (ViceChairman)
4teen4 GmbH, Germany, (Director)
DIADEM DX, Italy, (Chairman)
Dr Möller cofounded Adrenomed AG, a Biopharmaceutical company, served as Vice Chairman, from 12/17 to 8/19 as CEO and since 12/19 as Director. From 1975-1998, Dr. Moeller held several senior level positions in Germany, Japan, USA and the Netherlands with Boehringer Mannheim, including: Head of R&D Diagnostics; President of Decentralized Diagnostics; CEO of Boehringer Mannheim Therapeutics; and Chief Technology Officer of Corange, the holding company of Boehringer Mannheim. In 1995 he became CEO of the worldwide Boehringer Mannheim Group, which generated sales of >$4 billion in 1997. Following the sale of Boehringer Mannheim Group to Roche in 1998, Dr. Moeller was named Head of Global Development and Strategic Marketing Pharmaceuticals, as well as a member of Roche’s Executive Committee. Dr. Moeller left Roche in December 1998. Dr. Moeller received his Ph.D. in Physical Chemistry from the University of Kiel, Germany. He is married with 2 children.
Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.
Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with the National Cancer Institute and the acquisition of Pregenen. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and at PureTech Ventures, where he was a member of the founding team of Vedanta Biosciences. He also serves as a columnist for Nikkei Biotech, the leading biotech journal in Japan. Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.